PFAS and Pharmaceutical Resilience: Preparing for Wastewater Regulations with Innovative PFAS Destruction Technologies
Day 2 Supply & Formulation Excellence Stage
07/10/2026 15:45 - 16:10pm
Contributors
Eléonore Morlas : Chief Commercial Officer - Oxyle
PFAS-related regulation is emerging as a systemic risk for pharmaceutical manufacturing, with wastewater discharge under increasing scrutiny as authorities move beyond legacy long-chain compounds to short- and ultra-short-chain PFAS such as TFA. These smaller, more mobile compounds evade conventional treatment methods, leaving many sites unprepared for tightening discharge limits.
This session examines how pharmaceutical manufacturers can close that gap using innovative PFAS destruction technology. It will examine a case where TFA-contaminated effluent from a pharmaceutical manufacturer was treated using OxLight, an advanced photochemical reduction technology, achieving over 99% degradation with no harmful byproducts detected.